Mukka Proteins

Has Mukka Proteins declared dividend?

No Dividend History Available

Who are the peers of the Mukka Proteins?

Mukka Proteins' peers include Godavari Bioref., HMA Agro Inds., Aayush Wellness, and others, with Aayush Wellness showing excellent management risk and the highest 1-year return at 1374.42%, while Mukka Proteins has a 1-year return of -45.04%. Growth is good for Mukka Proteins and a few others, but its capital structure is below average compared to peers.

Peers: The peers of Mukka Proteins are Godavari Bioref., HMA Agro Inds., Andrew Yule & Co, Aayush Wellness, Jindal Photo, Vadilal Enterp., SKM Egg Prod., Foods & Inns, and Apex Frozen Food.<BR><BR>Quality Snapshot: Excellent management risk is observed at Aayush Wellness and the rest have Average management risk. Growth is Good at Mukka Proteins, Vadilal Enterp., SKM Egg Prod., and Aayush Wellness, while the rest show Below Average or Average growth. Capital Structure is Good at Aayush Wellness, Vadilal Enterp., and SKM Egg Prod., while Below Average capital structure is found at Mukka Proteins, Andrew Yule & Co, HMA Agro Inds., Jindal Photo, Foods & Inns, and the rest.<BR><BR>Return Snapshot: Aayush Wellness has the highest 1-year return at 1374.42%, while HMA Agro Inds. has the lowest at -42.55%, with Mukka Proteins' 1-year return of -45.04% being lower than both. Additionally, Jindal Photo and Foods & Inns are among the peers with negative six-month returns.

What does Mukka Proteins do?

Mukka Proteins Ltd is a micro-cap FMCG company that specializes in protein products, with recent net sales of ₹3,816 Cr and a net profit of ₹136 Cr as of March 2025. The company has a market cap of ₹897 Cr and key financial metrics include a P/E ratio of 19.00 and a debt-equity ratio of 0.93.

Overview:<BR>Mukka Proteins Ltd operates in the FMCG industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Mukka Proteins Limited was originally incorporated as "Mukka Sea Food Industries" in Karnataka on March 13, 2003. It was converted from a partnership firm to a private company on November 04, 2010. The latest quarterly results report net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3,816 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 136 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 897 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.93 <BR>Return on Equity: 10.47% <BR>Price to Book: 2.03 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the top shareholders of the Mukka Proteins?

The top shareholders of Mukka Proteins include Mohammed Haris K, who holds 30.23%, followed by 7 Foreign Institutional Investors with 2.63%, and Neomile Growth Fund - Series I with 1.98%. Individual investors own 19.85%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Mukka Proteins include the promoters, who hold the majority of the shares. The promoter with the highest holding is Mohammed Haris K, who owns 30.23% of the company. Additionally, there are 7 Foreign Institutional Investors (FIIs) holding a combined 2.63% of the shares. The highest public shareholder is Neomile Growth Fund - Series I, which holds 1.98%. Individual investors collectively own 19.85% of the company. There are no pledged promoter holdings, and no mutual funds are currently invested in Mukka Proteins.

How big is Mukka Proteins?

As of 24th July, Mukka Proteins Ltd has a market capitalization of 875.00 Cr, with recent net sales of 1006.42 Cr and a net profit of 46.16 Cr. The company reported shareholder's funds of 396.09 Cr and total assets of 940.79 Cr for the annual period ending March 2024.

As of 24th July, Mukka Proteins Ltd has a market capitalization of 875.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Mukka Proteins reported Net Sales of 1006.42 Cr and a Net Profit of 46.16 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds of 396.09 Cr and Total Assets amounting to 940.79 Cr.

How has been the historical performance of Mukka Proteins?

Mukka Proteins has shown fluctuating performance, with net sales declining to 1,006.42 Cr in March 2025 from 1,379.83 Cr in March 2024, alongside decreases in profitability, while total assets increased to 1,076.32 Cr. The company faced a challenging year marked by negative cash flow and reduced profits.

Answer:<BR>The historical performance of Mukka Proteins shows a fluctuating trend in net sales and profitability over the years, with a notable decline in the most recent fiscal year.<BR><BR>Breakdown:<BR>Mukka Proteins reported net sales of 1,006.42 Cr for the year ending March 2025, a decrease from 1,379.83 Cr in March 2024 and 1,177.12 Cr in March 2023, but an increase from 770.50 Cr in March 2022. Total operating income mirrored this trend, reaching 1,006.42 Cr in March 2025. The company's total expenditure, excluding depreciation, was 911.53 Cr in March 2025, down from 1,274.36 Cr in March 2024, while operating profit (PBDIT) was 110.01 Cr, showing a decline from 121.79 Cr in the previous year. Profit before tax also decreased to 59.20 Cr in March 2025 from 84.35 Cr in March 2024. Consequently, profit after tax fell to 47.03 Cr from 71.20 Cr. The company's total assets increased to 1,076.32 Cr in March 2025, up from 940.79 Cr in March 2024, and total liabilities also rose to 1,076.32 Cr from 940.79 Cr. Cash flow from operating activities remained negative at -111.00 Cr in March 2025, although cash and cash equivalents decreased to 3.00 Cr from 94.00 Cr in March 2024. Overall, Mukka Proteins experienced a challenging year with declining sales and profits, despite an increase in total assets and liabilities.

Is Mukka Proteins overvalued or undervalued?

As of November 14, 2025, Mukka Proteins is considered very attractive and undervalued with a PE ratio of 16.74 and an EV to EBITDA of 12.74, outperforming peers like Avanti Feeds and Apex Frozen Foods, and has delivered an 8.16% return compared to the Sensex's 1.62%.

As of 14 November 2025, Mukka Proteins has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, supported by a PE ratio of 16.74, an EV to EBITDA ratio of 12.74, and a PEG ratio of 0.00, indicating strong potential for growth relative to its price. <BR><BR>In comparison with peers, Avanti Feeds has a PE ratio of 16.54 and an EV to EBITDA of 10.04, while Apex Frozen Foods shows a significantly higher PE ratio of 43.53, suggesting that Mukka Proteins is positioned favorably within its industry. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, with an 8.16% return compared to the Sensex's 1.62%, reinforcing the notion of its undervaluation.

Is Mukka Proteins technically bullish or bearish?

As of December 3, 2025, Mukka Proteins is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and RSI across different timeframes.

As of 3 December 2025, the technical trend for Mukka Proteins has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands are also bearish. Although the weekly MACD and KST are mildly bullish, the overall sentiment is tempered by the bearish signals from the moving averages and Bollinger Bands. The RSI shows no signal on the weekly timeframe, while it is bullish on the monthly, indicating mixed signals across different timeframes. Overall, the bearish trend is currently stronger, reflecting the recent price decline from the previous close.

When is the next results date for Mukka Proteins Ltd?

The next results date for Mukka Proteins Ltd is 15 May 2026.

The next results date for Mukka Proteins Ltd is scheduled for 15 May 2026.

Are Mukka Proteins Ltd latest results good or bad?

Mukka Proteins Ltd's latest results are concerning, showing a 41.76% decline in Q4 FY26 net sales compared to the previous quarter, despite a 51.73% year-on-year increase in net profit. The company's heavy reliance on non-operating income and significant revenue volatility raise doubts about its long-term sustainability.

Mukka Proteins Ltd's latest results present a mixed picture, leaning more towards the negative side due to significant operational challenges. In Q4 FY26, the company reported net sales of ₹380.61 crores, which reflects a drastic decline of 41.76% compared to the previous quarter and a slight decrease of 0.25% year-on-year. This sharp drop follows an exceptional performance in Q3 FY26, where sales surged by 167.19%, indicating considerable volatility in revenue generation.<BR><BR>On the positive side, the consolidated net profit for Q4 FY26 was ₹20.62 crores, marking a year-on-year increase of 51.73%. The operating profit margin, excluding other income, improved to 9.21%, up from 7.84% in the same quarter last year. However, the company's heavy reliance on non-operating income, which constituted over 52% of profit before tax, raises concerns about the sustainability of these profit figures.<BR><BR>Overall, while there are some improvements in profitability metrics, the severe revenue volatility and negative operating cash flow—reported at ₹111 crores for FY25—highlight significant underlying issues. The stock has also underperformed compared to its peers and the broader FMCG sector, reflecting investor skepticism regarding its ability to deliver consistent value. Therefore, the latest results can be considered more concerning than encouraging.

Should I buy, sell or hold Mukka Proteins Ltd?

Why is Mukka Proteins Ltd falling/rising?

As of 25-May, Mukka Proteins Ltd's stock price is rising by 2.57%, despite recent underperformance compared to its sector and a negative year-to-date performance of -3.75%. The stock shows mixed signals in moving averages and decreased investor participation, indicating volatility.

As of 25-May, Mukka Proteins Ltd's stock price is currently rising, with a change of 0.58, or 2.57%, indicating a positive movement. This increase comes despite the stock's recent underperformance compared to its sector, where it lagged by 0.48%. <BR><BR>In terms of recent performance, the stock has shown a slight gain of 0.57% over the past week, although it has experienced a decline of 3.71% over the past month and a significant drop of 25.45% over the past year. The year-to-date performance is also negative at -3.75%, but it is noteworthy that the broader market, represented by the Sensex, has also faced challenges, with a year-to-date decline of 10.25%. <BR><BR>Today's trading activity indicates that while the stock is liquid enough for trading, there has been a notable decrease in investor participation, with delivery volume falling by 14.23% compared to the 5-day average. Additionally, the stock's moving averages show mixed signals; it is above the 50-day and 100-day moving averages but below the 5-day, 20-day, and 200-day moving averages, suggesting some volatility in its price trends.<BR><BR>Overall, while the stock is currently rising, it is important to consider the broader context of its recent performance and market conditions.

Which are the latest news on Mukka Proteins?